Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
31 hedge funds and large institutions have $56.7M invested in Sinovac Biotech, Ltd in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 9 closing their positions.
193% more call options, than puts
Call options by funds: $776K | Put options by funds: $265K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 35 → 31 (-4)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
56% less capital invested
Capital invested by funds: $128M → $56.7M (-$71.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.87M |
| 2 |
O
OrbiMed
New York
|
+$1.29M |
| 3 |
SIM
Spark Investment Management
New York
|
+$361K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$308K |
| 5 |
Barclays
London,
United Kingdom
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.68M |
| 2 |
GP
GLG Partners
London,
United Kingdom
|
-$3.65M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$699K |
| 4 |
Millennium Management
New York
|
-$409K |
| 5 |
Walleye Trading
New York
|
-$346K |
SVA Hedge Fund Activity: Q4 2017 in Review
31 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2017, worth a combined $56.7M — down 56% from $128M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SVA and 6 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.87M. The largest seller was Morgan Stanley, cutting an estimated $4.68M.
- 31 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2017, down from 35 in Q3 2017.
- Funds reported $56.7M of Sinovac Biotech, Ltd stock for Q4 2017, down 56% quarter-over-quarter.
- 6 funds opened new Sinovac Biotech, Ltd positions in Q4 2017 and 9 closed out, a net change of -3 holders.
- The largest Sinovac Biotech, Ltd buyer in Q4 2017 was Renaissance Technologies, an estimated $3.87M added.
- The largest Sinovac Biotech, Ltd seller in Q4 2017 was Morgan Stanley, an estimated $4.68M sold.
Based on aggregated 13F filings for Q4 2017.